TrialsgrambetaRCTs are beautiful

2025 ESC/EACTS Guidelines for the management of valvular heart disease

This guideline cites 10 of the 199 landmark trials in our Cardiology register.

The 2025 ESC/EACTS valvular guideline adopts lifetime management for aortic stenosis and lowers the age threshold at which TAVI becomes a reasonable option to ≥70 years (SAVR favoured below 70, Heart-Team decision in between). It also expands transcatheter mitral and tricuspid options. The register's landmark valve trials are grouped by lesion below.

Aortic stenosis: TAVI vs. SAVR5

  • 2024NOTION-2⁠Cardiology · Structural · TAVRIn 370 younger, low-risk patients (≤75 years) with severe aortic stenosis, transcatheter aortic-valve implantation was not shown non-inferior for 1-year death, stroke, or rehospitalisation compared with surgical aortic-valve replacement.10.2% vs 7.1%Read →
  • 2019PARTNER 3 Core⁠Cardiology · Structural · TAVRIn 1,000 patients with severe AS at low surgical risk, TAVR with the SAPIEN 3 valve reduced death, stroke or rehospitalisation at one year versus surgical AVR.HR 0.54Read →
  • 2019Evolut Low Risk⁠Cardiology · Structural · TAVRIn 1,468 patients with severe AS at low surgical risk, TAVR with a self-expanding valve was non-inferior to surgical aortic-valve replacement for death or disabling stroke at 2 years.5.3% vs 6.7%Read →
  • 2016PARTNER 2A⁠Cardiology · Structural · TAVRIn 2,032 intermediate-risk patients with severe aortic stenosis, transcatheter aortic-valve replacement was non-inferior for 2-year death or disabling stroke compared with surgical aortic-valve replacement.HR 0.8995% CI 0.73-1.09Read →
  • 2010PARTNER 1B Core⁠Cardiology · Structural · TAVRIn 358 patients with severe AS deemed inoperable, transcatheter aortic-valve replacement reduced all-cause mortality at 1 year compared with medical therapy.HR 0.55Read →

Asymptomatic severe AS: timing of intervention2

  • 2025EARLY TAVR⁠Cardiology · Structural · TAVRIn 901 patients with asymptomatic severe aortic stenosis, early TAVR reduced death, stroke or unplanned cardiovascular hospitalisation compared with clinical surveillance.HR 0.5Read →
  • 2022AVATAR⁠Cardiology · Structural · early AVRIn 157 patients with asymptomatic severe aortic stenosis, early aortic valve replacement reduced death, MI, stroke, or HF hospitalisation compared with watchful waiting.HR 0.4695% CI 0.23-0.90Read →

Mitral regurgitation: transcatheter repair2

  • 2018COAPT Core⁠Cardiology · Structural · MitralIn 614 patients with HF and severe secondary mitral regurgitation, MitraClip plus GDMT reduced HF hospitalisation and all-cause mortality compared with GDMT alone.HR 0.53Read →
  • 2018MITRA-FR⁠Cardiology · Structural · MitralIn 304 patients with heart failure and severe secondary mitral regurgitation, transcatheter mitral repair did not reduce death or heart-failure hospitalisation compared with medical therapy alone.OR 1.1695% CI 0.73-1.84Read →

Tricuspid regurgitation1

  • 2023TRILUMINATE⁠Cardiology · Structural · TricuspidIn 350 patients with severe symptomatic tricuspid regurgitation, transcatheter tricuspid repair improved quality of life compared with medical therapy.WR 1.48Read →

Cited landmark trials not yet in the register4

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2011PARTNER 1A

    TAVI vs. surgery in high-risk aortic stenosis.

  • 2017SURTAVI

    Self-expanding TAVI vs. surgery in intermediate risk.

  • 2024RESHAPE-HF2

    Transcatheter edge-to-edge repair in functional MR.

  • 2024TRISCEND II

    Transcatheter tricuspid valve replacement in severe TR.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.